Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Akari Therapeutics Plc (AKTX)

Akari Therapeutics closes final private placement tranche, issuing 980,395 ADSs

Neutral Impact 3 of 5 financing Written later

Akari Therapeutics amended its securities purchase agreement on June 23, 2026, combining its second and third closings into one. On June 26, 2026, it issued the remaining 980,395 ADSs, or prefunded warrants in lieu of them, completing the private placement. Delivery of the Series H, I and J warrants depends on shareholder approval at the annual general meeting on June 30, 2026.

Key points

  • Offering originally covered 1,470,588 unregistered ADSs or prefunded warrants, funded in three tranches
  • First closing occurred May 27, 2026; the second and third closings were combined into one on June 26, 2026
  • Remaining 980,395 ADSs or prefunded warrants were issued on the combined closing date
  • Series H, I and J warrants are contingent on shareholder approval at the June 30, 2026 annual general meeting

The filing

CompanyAkari Therapeutics Plc (AKTX)
Form8-K, current report
Filed with the SECJun 26, 2026, 5:15 PM ET
Accession number0001493152-26-030341

Items reported: 1.01 Material Definitive Agreement

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 26, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.